CARL ZEISS MEDITEC ADR 1 (AFXA) — Cash Flow-to-Debt Ratio
CARL ZEISS MEDITEC ADR 1 (AFXA) has a Cash Flow-to-Debt Ratio of 0.11x as of September 2025, meaning its operating cash flow of €144.16 Million could theoretically repay 0% of its total liabilities (€1.28 Billion) in one year. See CARL ZEISS MEDITEC ADR 1 (AFXA) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CARL ZEISS MEDITEC ADR 1 Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for CARL ZEISS MEDITEC ADR 1 across 4 annual periods. For the full cash flow conversion analysis, see CARL ZEISS MEDITEC ADR 1 cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for CARL ZEISS MEDITEC ADR 1 (2022–2025)
Year-by-year debt coverage analysis for CARL ZEISS MEDITEC ADR 1. Check how high is CARL ZEISS MEDITEC ADR 1's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | €209.86 Million | €1.28 Billion | ▼ -11.1% |
| 2024 | 0.19x | €247.32 Million | €1.34 Billion | ▼ -36.6% |
| 2023 | 0.29x | €250.86 Million | €860.02 Million | ▲ +22.9% |
| 2022 | 0.24x | €188.20 Million | €792.73 Million | — |